Clinical Trials

MAUI, Hawaii — Postmarketing, or phase 4, clinical trials can provide physicians and researchers with a broad range of information, from long-term safety findings to sales or marketing data, according to a presentation at the 2020 Rheumatology Winter Clinical Symposium.

An “exceedingly low” percentage of patients with cancer enroll in clinical trials as the first course of therapy, according to results of a study conducted at Penn State College of Medicine and published in Journal of the National Comprehensive Cancer Network.

Patients with cancer often feel overwhelmed by the reality of their disease and may struggle simply to maintain the course of treatment set forth by their oncologist. The additional effort required to seek out appropriate clinical trials, determine their eligibility and travel to trial sites may be more than their limited schedules, finances and emotional reserves permit.

Less than 5% of eligible adults participate in cancer clinical trials, even in the information age when more opportunities exist than ever before to raise awareness of these trials and facilitate patient recruitment.

CHICAGO — The use of real-world evidence together with randomized controlled trial data can provide further insight into the effectiveness and safety of drugs for diabetes and cardiovascular disease in real-life clinical settings, according to a speaker at the Cardiometabolic Health Congress.

There is compelling evidence that reducing variability in cancer care can improve patient outcomes and limit costs.

Exciting developments in molecular oncology within the past few months include impressive clinical results of a novel drug that targets RET fusions, evidence for variability in gene mutation allele-specific therapy responses, a novel MEK1 resistance mechanism, and an emerging complexity about differences between oncogenic driver mutations regarding the biology of cancer in a given tissue of origin.

Two trials presented at the 2013 American Heart Association Scientific Sessions and a third trial, all simultaneously published online last year in The New England Journal of Medicine, come to divergent conclusions and leave many wondering if the data may spell the end for pharmacogenomic-guided dosing of warfarin.

The racial disparities that exist in the treatment and management of patients with multiple myeloma have been examined and charted for years, even decades.

Healio spoke with Ryan. W. Jacobs, MD, about complications that can arise in patients with CLL.